Mechanisms of carbapenem resistance in gram-negative pathogens.

Kim Tian*

Department of molecular biology, Nanjing Medical University, Nanjing, China.

Introduction

Carbapenems are broad-spectrum β-lactam antibiotics that play a crucial role in treating severe infections caused by multidrug-resistant bacteria. They are particularly effective against Gram-negative organisms such as Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae, as well as some Gram-positive bacteria including Staphylococcus aureus and Streptococcus pneumoniae [1]. However, the widespread use of carbapenems has led to the emergence of resistance mechanisms, posing significant challenges in clinical management. This essay explores the susceptibility rates of carbapenems against both Gram-positive and Gram-negative bacteria, and discusses their correlation with antibiotic consumption trends [2].

Carbapenem resistance among Gram-negative bacteria is a growing concern globally. The mechanisms of resistance include the production of carbapenemases, efflux pumps, and porin mutations, which reduce drug efficacy. In contrast, Gram-positive bacteria generally exhibit higher susceptibility to carbapenems due to differences in cell wall structure and resistance mechanisms [3].

Studies have shown varying susceptibility rates among different bacterial species. For instance, Carbapenem-Resistant Enterobacteriaceae (CRE) strains have become increasingly prevalent, especially in healthcare settings where selective pressure from antibiotic use is high. Conversely, Gram-positive bacteria like Methicillin-Resistant Staphylococcus Aureus (MRSA) generally show lower resistance rates to carbapenems, although resistance can develop over time [4].

Factors influencing carbapenem resistance

1. **Antibiotic Consumption Trends:** The misuse and overuse of antibiotics, including carbapenems, contribute significantly to the development of resistance. High consumption rates correlate with increased resistance rates among both Gram-positive and Gram-negative bacteria [5].

2**. Healthcare Settings:** Hospitals and long-term care facilities are hotspots for antibiotic-resistant infections due to the concentration of vulnerable patients, frequent antibiotic use, and potential for cross-transmission of resistant strains [6].

3. **Genetic Adaptation:** Bacteria possess inherent genetic plasticity that allows them to acquire resistance genes through horizontal gene transfer and mutations. This genetic adaptation accelerates the emergence of resistant strains [7].

become limited, requiring the use of last-resort antibiotics such as colistin or tigecycline, which are associated with higher toxicity and poorer outcomes. In contrast, carbapenem-resistant Gram-positive infections, while less common, also necessitate alternative treatment strategies and careful consideration of antibiotic stewardship principles [8].

Antibiotic stewardship programs play a pivotal role in combating carbapenem resistance. These programs promote judicious antibiotic use, optimize dosing regimens, and implement infection control measures to prevent transmission of resistant pathogens. Surveillance of resistance patterns and molecular epidemiology helps identify emerging resistance trends and guide empirical therapy decisions [9].

Future research efforts should focus on developing novel antibiotics with improved efficacy against carbapenem-resistant pathogens. Additionally, strategies to enhance infection prevention and control measures in healthcare settings are essential for reducing the spread of resistant bacteria [10].

Conclusion

In conclusion, carbapenem susceptibility rates vary significantly between Gram-positive and Gram-negative bacteria, influenced by antibiotic consumption patterns and resistance mechanisms. While Gram-positive bacteria generally exhibit higher susceptibility, increasing rates of carbapenem resistance among Gram-negative pathogens present a formidable clinical challenge. Effective antibiotic stewardship, infection control practices, and continued research are crucial in addressing these challenges and preserving the effectiveness of carbapenems in clinical practice.

References

1. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Med. 2012;27(2):128.
2. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86.
3. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect. 2014;20(9):821-30.

***Correspondence to:** Kim Tian**,** Department of molecular biology, Nanjing Medical University, Nanjing, China, E-mail: ktianim@163.com

***Received:** 07-June-2024, Manuscript No. AACPLM-24-141971; **Editor assigned:** 08-June-2024, PreQC No. AACPLM-24-141971 (PQ); **Reviewed:** 22-June-2024, QC No AACPLM-24-141971; **Revised:** 26-June-2024, Manuscript No. AACPLM -24-141971 (R); **Published:** 29-June-2024, DOI: 10.35841/aacplm-6.3.215*

***Citation:** Tian K. Mechanisms of Carbapenem Resistance in Gram-Negative Pathogens. J Clin Path Lab Med. 2024;6(3):215.*

4. Woodford N, Wareham DW, Guerra B, et al. Carbapenemase-producing Enterobacteriaceae and non-Enterobacteriaceae from animals and the environment: an emerging public health risk of our own making?. J Antimicrob Chemother. 2014;69(2):287-91.
5. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55(7):943-50..
6. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12(9):826-36.
7. Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. TRENDS in Microbiol. 2006;14(9):413-20.
8. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20(3):440-58.
9. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1-2.
10. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-β-lactamases: a last frontier for β-lactams?. Lancet Infect Dis. 2011;11(5):381-93.

Citation: *Tian K. Mechanisms of Carbapenem Resistance in Gram-Negative Pathogens. J Clin Path Lab Med. 2024;6(3):215.*